The Valley Desk

NCT04434040 · Interventional trial

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Overall registry status Recruiting

Phase 2

Conditions Breast Cancer, Circulating Tumor DNA, Residual Cancer, Triple Negative Breast Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov